BioArctic
Tracked across 3 events · 38 articles · First seen Feb 06, 2026 · Last active Mar 27, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
BioArctic reported record financial results for 2025, with an operating profit exceeding SEK 1.2 billion and a doubled cash position. The company's Lecanemab drug, developed with Eisai, continues to gain regulatory approvals and market penetration globally, contributing significantly to royalty revenues. BioArctic also expanded its pipeline with new projects in Huntington's and Parkinson's diseases and proposed a dividend of SEK 2.00 per share.
Feb 06, 2026 · 23 articles
Regulatory
BioArctic, as the inventor of Leqembi, stands to benefit significantly from the expanded market access and potential for increased sales in China. The priority review designation for the subcutaneous formulation of Leqembi in China is a positive development for BioArctic.
Feb 09, 2026 · 7 articles
Tech
BioArctic, as the inventor of lecanemab and developer of exidavnemab, will present new data at the AD/PD 2026 conference, highlighting its ongoing research and development in neurodegenerative diseases. The company stands to benefit from the continued success and expansion of lecanemab's market reach.
Mar 11, 2026 · 8 articles
Eisai
partner
↔
BioArctic
BioArctic and Eisai are partners in the development and commercialization of Lec
Lars Lannfelt
inventor
↔
BioArctic
Professor Lars Lannfelt's work led to the development of Leqembi by BioArctic.
NEWSDESK
Track BioArctic live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard